Previous close | 82.73 |
Open | 84.61 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 84.61 - 84.61 |
52-week range | 72.98 - 93.58 |
Volume | |
Avg. volume | 72,632 |
Market cap | 185.193B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 27.65 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.49 (4.22%) |
Ex-dividend date | 09 Mar 2023 |
1y target est | N/A |
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
NVS earnings call for the period ending December 31, 2022.
Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.